-
New advances in cervical cancer immunotherapy The BLA of batilimumab was granted priority review by the FDA
Time of Update: 2021-09-07
Recently, Agenus announced that the FDA has accepted its PD-1 monoclonal antibody balstilimab (batilimumab) to treat recurrent or metastatic cervical cancer that has progressed during or after chemotherapy a biological product license application (BLA).
-
US$2.3 billion to help develop ready-to-use natural killer cell therapy Kite to reach a partnership
Time of Update: 2021-09-07
This collaboration will combine Shoreline's deep expertise in induced pluripotent stem cell (iPSC) differentiation and gene reprogramming, and Kite's extensive cell therapy development technology, commercialization and production capabilities to jointly develop a series of innovations for the treatment of hematological malignancies Allogeneic (allogeneic) candidate therapy .
-
Reduce the mortality of specific hospitalized patients by 20%, the phase 3 clinical results of the new crown neutralizing antibody combination are positive
Time of Update: 2021-09-07
On June 16, 2021, Regeneron announced that its research neutralizing antibody therapy REGEN-COV (casirivimab and imdevimab) has obtained positive preliminary results in the Phase 3 clinical trial RECOVERY .
-
ASCO's research targets worthy of in-depth attention in 2021
Time of Update: 2021-09-07
1 Cyteir's product pipeline03 ASCO's summary introduction to RAD51 in 202103 ASCO's summary introduction to RAD51 in 2021The introduction of the RAD51 target and related inhibitor CYT-0851 at the 2021 ASCO Conference is mainly distributed in two report abstracts, namely Cyteir Therapeutics' first phase I/II human clinical trial study of CYT-0851 for advanced solid tumors and hematological cancers.
-
Announcement of Phase Ⅱ Clinical Data of KN046 Combined with Chemotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma
Time of Update: 2021-09-07
Phase II clinical study data of the sex antibody KN046 combined with paclitaxel/cisplatin in the first-line treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) (study number: KN046-204) .
-
Microchip Bio: Chidamide was approved for marketing in Japan
Time of Update: 2021-09-07
On the 24th, Microchip announced that the company’s partner Huya Bio-International has recently received approval from the Japan Pharmaceuticals and Medical Devices Agency (PMDA) to approve the listing of chidamide for monotherapy in the treatment of relapsed or refractory (R /R) Adult T-cell leukemia (ATL) .
The original innovative drug was approved for listing overseas .
-
Innovent's FGFR small molecule inhibitor Pemigatinib was approved in the Taiwan market
Time of Update: 2021-09-07
Today, Cinda Biotech announced that pemigatinib has been approved by the Food and Drug Administration (TFDA) of the Ministry of Health and Welfare of Taiwan for the treatment of adults who have received systemic drug therapy and tumors with fibroblast growth factor receptor 2 (FGFR2) Locally advanced or metastatic cholangiocarcinoma that is fused or rearranged and cannot be resected .
-
Preliminary clinical results of HER3-targeted ADC for non-small cell lung cancer are positive
Time of Update: 2021-09-07
On June 4, 2021, Daiichi Sankyo announced that its research antibody conjugate (ADC) patritumab deruxtecan, targeting HER3, is in the treatment of non-small cell lung cancer (NSCLC) with drug-resistant EGFR mutations.
-
Overcome resistance to PARP inhibitors "old" antibiotics show "new" anti-cancer potential
Time of Update: 2021-09-07
In a new study published recently in the journal Nature Cancer, researchers found that an antibiotic discovered in the 1950s, novobiocin (NVB), can effectively kill DNA carrying homologous recombination (HR) Repair defective tumor cells .
-
The overall response rate is 66.3%, and the mid-term results of the key clinical trial of innovative ADC are positive.
Time of Update: 2021-09-07
On June 22, 2021, ADC Therapeutics announced that its new antibody-conjugated drug (ADC) camidanlumab tesirine (Cami), which targets CD25, is in a pivotal phase 2 clinical trial for the treatment of patients with relapsed/refractory Hodgkin’s lymphoma Positive results .
-
A breakthrough in stem cell transplantation therapy for the treatment of type 1 diabetes
Time of Update: 2021-09-07
On June 25, 2021, ViaCyte announced that in patients with type 1 diabetes (T1D), its in-study stem cell-derived islet cell replacement therapy PEC Direct (VC-02) has obtained positive preliminary clinical results .
-
Novartis Radioligand Therapy for the Treatment of Prostate Cancer Receives FDA Breakthrough Therapy Designation
Time of Update: 2021-09-07
On June 16, 2021, Novartis announced that the US FDA has granted its potential "first-in-class" targeted radioligand therapy (radioligand therapy, RLT) 177Lu-PSMA-617 breakthrough therapy designation for Treatment of prostate specific membrane antigen (PSMA) positive castration resistant prostate cancer (mCRPC) .
-
Blue Sail Medical: BioFreedom stent and RISE NC balloon dilatation catheter obtained product registration certificate
Time of Update: 2021-09-07
It is understood that BioFreedom™ is the world's first recommended stent that has been validated by clinical trials and written into the European Cardiovascular Treatment Guidelines for patients with high bleeding risk .
Especially suitable for patients with high bleeding risk .
-
Fully absorbable pacemaker comes out
Time of Update: 2021-09-06
This time, a team led by Northwestern University researchers Reese Arora, Igor Ivmov, and John Rogers developed a fully implanted, thin and lightweight pacemaker for use in Control heart rate and heart rhythm after surgery .
-
2021 SCI Impact Factor Update Divine Journal CA finally breaks 500 points
Time of Update: 2021-09-06
In addition to CA, the top four medical journals NEJM, The Lancet, JAMA and BMJ also have good impact factors.
The impact factors of the four world-renowned journals, Nature, Science, Cell, and PNAS, have also been greatly improved .
-
Two major health-threatening "killers" viruses and cancer cells meet who will "die"
Time of Update: 2021-09-06
In order to use oncolytic viruses more effectively and find biomarkers that help identify H-1PV susceptibility, the research team analyzed the protein genes located on the surface of cancer cells to characterize their role in the process of docking with the virus .
-
Bayer's first-in-class therapy is approved for alleviating the progression of chronic kidney disease and reducing cardiovascular risk
Time of Update: 2021-09-06
S. FDA has approved the company’s “first-in-class” therapy Kerendia (finerenone) to be used to reduce renal function in type 2 diabetic patients with chronic kidney disease (CKD).
Retrieved July 9, 2021, from https:// en/Bayer%E2%80%99s-KERENDIA%C2%AE-finerenone-Receives-US-FDA-Approval-for-Treatment-of-Patients-with-Chronic-Kidney-Disease-Associated-with-Type-2- Diabetes[2] George L.
-
Bone Research: Targeting angiogenesis to treat inflammatory fractures of nonunion
Time of Update: 2021-09-06
Arthritis mice fracture nonunion, fracture callus disappears, angiogenesis is reduced, and the formation of fibrotic scar tissue leads to failure of biomechanical properties, which are the main manifestations of clinical atrophic fracture nonunion .
-
BMS immunocombination therapy Opdivo+Yervoy first-line treatment of head and neck cancer stage 3 clinical failure
Time of Update: 2021-09-06
The trial is carried out in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN) who are eligible for platinum therapy, and the anti-PD-1 therapy Opdivo (Odivo, generic name: nivolumab, nivolumab) is being evaluated Efficacy and safety of combined therapy with anti-CTLA-4 therapy Yervoy (ipilimumab) and standard care program EXTREME (cetuximab+cisplatin/carboplatin+fluorouracil) for first-line treatment .
-
How to supervise human genome editing?
Time of Update: 2021-09-06
Today, the World Health Organization (WHO) issued two reports that provide recommendations for the editing of the human genome, with the aim of making it a better tool for public health .
